Position in DFTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
-$4,918,554 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
2 quarters on record
Derivatives in DFTX
reported options exposure · as of Jun 30, 2026CallValue
$19,940,256
CallShares
423,900
PutValue
$15,415,008
PutShares
327,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026JANE STREET GROUP, LLC holds $1,364,130,252 across 291 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
2,934,193 | $218,538,693 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
191,541 | $102,847,939 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
403,995 | $98,885,855 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
1,752,646 | $96,290,370 | |
| 5 | EXEL |
Exelixis, Inc.
|
1,402,438 | $76,306,651 | |
| 6 | QURE |
uniQure N.V.
|
1,610,483 | $74,178,846 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
694,684 | $54,372,915 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
938,699 | $53,327,489 |
All Filings in DFTX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,940,256 | 423,900 | Call | Defined | 2026-08-14 | |
| 2026-06-30 | $15,415,008 | 327,700 | Put | Defined | 2026-08-14 | |
| 2026-03-31 | $652,050 | 34,500 | Put | Defined | 2026-05-12 | |
| 2026-03-31 | $996,030 | 52,700 | Call | Defined | 2026-05-12 | |
| 2026-03-31 | $4,918,554 | 260,241 | Shares | Defined | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||